

OncoGeneDx: Colorectal Cancer Panel

Panel Gene List: *APC, ATM, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM**, *MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SCG5/GREM1**, *SMAD4, STK11, TP53*

*Testing includes sequencing and deletion/duplication analysis for all genes except *EPCAM* (del/dup only) and *SCG5/GREM1* (del/dup only).

Clinical Features:

Individuals in the general population have an approximately 4.3% lifetime risk of developing colorectal cancer.¹ Most cases of colorectal cancer develop sporadically. Approximately 5-10% of colorectal cancers are due to a hereditary predisposition. Individuals with hereditary colorectal cancer syndromes often have a high risk of developing gastrointestinal cancers and require increased screening and surveillance to reduce their cancer risk. The features suggestive of a hereditary colorectal cancer predisposition include: young age at diagnosis, history of colorectal cancer or multiple polyps in one or more close relatives, multiple primary cancers in a single individual, and several relatives affected with cancer spanning multiple generations.

Of the cases that are suspected of having a hereditary predisposition to colorectal cancer, the most common causes are Lynch syndrome, due to pathogenic *MLH1, MSH2, MSH6, PMS2* variants and *EPCAM* deletions, as well as Familial Adenomatous Polyposis (FAP) and Attenuated FAP (AFAP) due to pathogenic *APC* variants. The other 14 genes on this panel account for an additional proportion of hereditary colorectal cancer cases.

The genes included on this panel have been shown to cause an increased risk for colorectal cancer and, in many cases, other cancers as well. Newer genes, such as *AXIN2* and *NTHL1*, have been identified in families with colorectal cancer and have been included in the panel to make it as comprehensive as possible. The evidence available to date may be derived from a small number of patients with wide confidence intervals or is based upon an ethnic cohort with one specific variant. Accurate risk assessment may be complicated by the low penetrance of pathogenic variants in these genes and/or ascertainment bias.

Inheritance Pattern:

Most genes on this panel are associated with an autosomal dominant cancer risk with the exception of *MUTYH* and *NTHL1*, which are associated with an autosomal recessive cancer risk. Some of the genes on this panel are also associated with extremely rare conditions when inherited in an autosomal recessive fashion. The specifics of this inheritance are outlined in the table below.

Test Methods:

Genomic DNA is extracted from the submitted specimen. For skin punch biopsies, fibroblasts are cultured and used for DNA extraction. This DNA is enriched for the complete coding regions and splice site junctions of the genes on this panel using a proprietary targeted capture system developed by GeneDx for next generation sequencing with CNV calling (NGS-CNV). For *PTEN* nucleotides c.-700 through c.-1300 in the promoter region, and for *APC*, promoters 1A and 1B are also captured. The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons. Concurrent *MSH2* Exons 1-7 Inversion analysis from NGS data is also performed. For *EPCAM* and *SCG5*, deletion/duplication analysis, but not sequencing, is performed. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

Test Sensitivity:

The clinical sensitivity of sequencing and deletion/duplication analysis of the 20 genes included in the OncoGeneDx Colorectal Cancer Panel depends in part on the patient's clinical phenotype and family history. In general, the sensitivity is highest for individuals with features suggestive of a hereditary predisposition to cancer as outlined above. DNA sequencing will detect nucleotide substitutions and small insertions and deletions, while NGS-CNV analysis, array CGH, or MLPA will detect exon-level deletions and duplications. These methods are expected to be greater than 99% sensitive in detecting pathogenic variants identifiable by sequencing or CNV technology.

Genetic testing using the methods applied at GeneDx is expected to be highly accurate. Normal findings do not rule out the diagnosis of a genetic disorder since some genetic abnormalities may be undetectable by this test. The methods used cannot reliably detect deletions of 20bp to 250bp in size, or insertions of 10bp to 250 bp in size. Sequencing cannot detect low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect mosaicism and cannot identify balanced chromosome aberrations. Rarely, incidental findings of large chromosomal rearrangements outside the gene of interest may be identified. Regions of certain genes have inherent sequence properties (for example: repeat, homology, or pseudogene regions, high GC content, rare polymorphisms) that yield suboptimal data, potentially impairing accuracy of the results. False negatives may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. In individuals with active or chronic hematologic neoplasms or conditions, there is a possibility

that testing may detect an acquired somatic variant, resulting in a false positive result. As the ability to detect genetic variants and naming conventions can differ among laboratories, rare false negative results may occur when no positive control is provided for testing of a specific variant identified at another laboratory. The chance of a false positive or false negative result due to laboratory errors incurred during any phase of testing cannot be completely excluded. Interpretations are made with the assumption that any clinical information provided, including family relationships, are accurate. Consultation with a genetics professional is recommended for interpretation of results.

Gene	Protein	Inheritance	Disease Associations
<i>APC</i> ²⁻⁵	ADENOMATOUS POLYPOSIS COLI PROTEIN	AD	Familial Adenomatous Polyposis (FAP)-associated condition: colorectal, duodenal or periampullary, gastric, thyroid, pancreatic, brain (medulloblastoma) & liver (hepatoblastoma) cancers, desmoid tumors, gastrointestinal polyps
<i>ATM</i> ⁶⁻¹¹	SERINE-PROTEIN KINASE ATM	AD	Breast, colon & pancreatic cancers
		AR	Ataxia telangiectasia
<i>AXIN2</i> ^{12,13}	AXIN-2	AD	Colon cancer, colon polyps
<i>BMPR1A</i> ^{2,14-16}	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1A	AD	Juvenile Polyposis syndrome (JPS): colorectal, gastric (if gastric polyps), small bowel & pancreatic cancer, gastrointestinal polyps
<i>CDH1</i> ¹⁷⁻²³	CADHERIN 1	AD	Hereditary Diffuse Gastric Cancer (HDGC) syndrome: gastric (diffuse), breast & colon (signet ring) cancer
<i>CHEK2</i> ^{6,7,24-31}	SERINE/THREONINE-PROTEIN KINASE CHK2	AD	Breast, colon, prostate, gastric & thyroid cancer
<i>EPCAM</i> ³²⁻³⁷	EPITHELIAL CELL ADHESION MOLECULE	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome

Gene	Protein	Inheritance	Disease Associations
<i>MLH1</i> ^{32,34-39}	DNA MISMATCH REPAIR PROTEIN MLH1	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MSH2</i> ³²⁻³⁹	DNA MISMATCH REPAIR PROTEIN MSH2	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MSH6</i> ^{32,34-38,40}	DNA MISMATCH REPAIR PROTEIN MSH6	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome
<i>MUTYH</i> ^{2,3,41-51}	ADENINE DNA GLYCOSYLASE	AR	<i>MUTYH</i> -associated polyposis (MAP): colorectal, small bowel & endometrial serous cancer, gastrointestinal polyps
<i>NTHL1</i> ⁵²⁻⁵⁵	ENDONUCLEASE III-LIKE 1	AR	Colon cancer, colon polyps
<i>PMS2</i> ^{32,34-37,56,57}	MISMATCH REPAIR ENDONUCLEASE PMS2	AD	Lynch syndrome (LS): colorectal, endometrial, ovarian, gastric, pancreatic, biliary tract, urinary tract, small bowel, prostate & brain cancer, sebaceous neoplasms
		AR	Constitutional mismatch repair deficiency syndrome

Gene	Protein	Inheritance	Disease Associations
<i>POLD1</i> ^{58,59}	DNA POLYMERASE DELTA CATALYTIC SUBUNIT	AD	Colon & endometrial cancer, colon polyps
<i>POLE</i> ^{58,60-62}	DNA POLYMERASE EPSILON CATALYTIC SUBUNIT A	AD	Colon cancer, gastrointestinal polyps
		AR	Facial dysmorphism, immunodeficiency, livedo, and short stature (FILS)
<i>PTEN</i> ^{2,63-66}	PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE 3-PHOSPHATASE AND DUAL-SPECIFICITY PROTEIN PHOSPHATASE PTEN	AD	<i>PTEN</i> hamartoma tumor syndrome (PHTS): breast, thyroid, endometrial, colon, melanoma & renal cancer, gastrointestinal polyps, Lhermitte-Duclos disease
<i>SCG5/ GREM1</i> ^{15,67,68}	NEUROENDOCRINE PROTEIN 7B2/GREMLIN-1	AD	Hereditary Mixed Polyposis syndrome (HMPS): colon cancer, colon polyps
<i>SMAD4</i> ^{2,14,16,69,70}	MOTHERS AGAINST DECAPENTAPLEGGIC HOMOLOG 4	AD	Juvenile Polyposis syndrome (JPS): colorectal, gastric (if gastric polyps), small bowel & pancreatic cancer, gastrointestinal polyps
<i>STK11</i> ^{2,71-73}	SERINE/THREONINE-PROTEIN KINASE STK11	AD	Peutz-Jeghers syndrome (PJS): breast, colorectal, pancreatic, gastric, small bowel, ovarian, lung, cervical & endometrial cancer, testicular tumors (LCCSCT), gastrointestinal polyps
<i>TP53</i> ^{24,74-78}	CELLULAR TUMOR ANTIGEN P53	AD	Li-Fraumeni syndrome (LFS): breast cancer, sarcoma, brain cancer, hematologic malignancies, adrenocortical carcinoma, among others**

Because of evolving and expanding phenotypes, this list of cancer/tumor types is not exhaustive. Gene-specific risk for some of the cancers and other features listed are not well-defined.

** High overall risk of cancer: 75% lifetime risk for males to develop cancer, nearly 100% risk for females.

Abbreviations:

AD – Autosomal Dominant

AR – Autosomal Recessive

CGH – Comparative genomic hybridization

LCCSCT – Large cell-calcifying Sertoli cell tumors

MLPA - Multiplex ligation-dependent probe amplification

References:

1. Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. SEER Cancer Statistics Review, 1975-2012: Lifetime Risk Tables (URL: <http://surveillance.cancer.gov/devcan>) [October 2016 accessed].
2. Jasperson, K. W. Genetic testing by cancer site: colon (polyposis syndromes). *Cancer J. Sudbury Mass* **18**, 328–333 (2012).
3. Sieber, O. M. et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N. Engl. J. Med.* **348**, 791–799 (2003).
4. Leoz, M. L., Carballal, S., Moreira, L., Ocaña, T. & Balaguer, F. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. *Appl. Clin. Genet.* **8**, 95–107 (2015).
5. Alkhouri, N., Franciosi, J. P. & Mamula, P. Familial adenomatous polyposis in children and adolescents. *J. Pediatr. Gastroenterol. Nutr.* **51**, 727–732 (2010).
6. Byrnes, G. B., Southey, M. C. & Hopper, J. L. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? *Breast Cancer Res. BCR* **10**, 208 (2008).
7. Einarsdóttir, K. et al. Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. *Hum. Mol. Genet.* **16**, 154–164 (2007).
8. Renwick, A. et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat. Genet.* **38**, 873–875 (2006).
9. Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov.* **2**, 41–46 (2012).
10. Tavtigian, S. V. et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. *Am. J. Hum. Genet.* **85**, 427–446 (2009).
11. Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. *J. Natl. Cancer Inst.* **97**, 813–822 (2005).
12. Marvin, M. L. et al. AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. *Am. J. Med. Genet. A.* **155A**, 898–902 (2011).
13. Lammi, L. et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. *Am. J. Hum. Genet.* **74**, 1043–1050 (2004).
14. Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and familial colon cancer. *Gastroenterology* **138**, 2044–2058 (2010).
15. Rohlin, A. et al. GREM1 and POLE variants in hereditary colorectal cancer syndromes. *Genes. Chromosomes Cancer* **55**, 95–106 (2016).
16. Brosens, L. A. A. et al. Risk of colorectal cancer in juvenile polyposis. *Gut* **56**, 965–967 (2007).
17. Fitzgerald, R. C. et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *J. Med. Genet.* **47**, 436–444 (2010).
18. Kaurah, P. et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* **297**, 2360–2372 (2007).
19. Petridis, C. et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. *Br. J. Cancer* **110**, 1053–1057 (2014).
20. Pharoah, P. D., Guilford, P., Caldas, C. & International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* **121**, 1348–1353 (2001).
21. Schrader, K. A. et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. *J. Med. Genet.* **48**, 64–68 (2011).
22. Brooks-Wilson, A. R. et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. *J. Med. Genet.* **41**, 508–517 (2004).
23. Guilford, P. et al. E-cadherin germline mutations in familial gastric cancer. *Nature* **392**, 402–405 (1998).
24. Pennington, K. P. et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. *Cancer* **119**, 332–338 (2013).
25. Cybulski, C. et al. CHEK2 is a multiorgan cancer susceptibility gene. *Am. J. Hum. Genet.* **75**, 1131–1135 (2004).
26. Dong, X. et al. Mutations in CHEK2 associated with prostate cancer risk. *Am. J. Hum. Genet.* **72**, 270–280 (2003).
27. Han, F., Guo, C. & Liu, L. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. *DNA Cell Biol.* **32**, 329–335 (2013).
28. Kilpivaara, O., Alhopuro, P., Vahteristo, P., Aaltonen, L. A. & Nevanlinna, H. CHEK2 I157T associates with familial and sporadic colorectal cancer. *J. Med. Genet.* **43**, e34 (2006).
29. Liu, C., Wang, Q.-S. & Wang, Y.-J. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. *Asian Pac. J. Cancer Prev. APJCP* **13**, 2051–2055 (2012).
30. Seppälä, E. H. et al. CHEK2 variants associate with hereditary prostate cancer. *Br. J. Cancer* **89**, 1966–1970 (2003).
31. Suchy, J. et al. CHEK2 mutations and HNPCC-related colorectal cancer. *Int. J. Cancer* **126**, 3005–3009 (2010).
32. Weissman, S. M. et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review. *J. Genet. Couns.* **20**, 5–19 (2011).
33. Li-Chang, H. H. et al. Colorectal cancer in a 9-year-old due to combined EPCAM and MSH2 germline mutations: case report of a unique genotype and immunophenotype. *J. Clin. Pathol.* **66**, 631–633 (2013).
34. Durno, C. A., Holter, S., Sherman, P. M. & Gallinger, S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. *Am. J. Gastroenterol.* **105**, 2449–2456 (2010).
35. Vasen, H. F. et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology* **110**, 1020–1027 (1996).
36. Wimmer, K. & Kratz, C. P. Constitutional mismatch repair-deficiency syndrome. *Haematologica* **95**, 699–701 (2010).
37. Win, A. K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **30**, 958–964 (2012).
38. Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* **305**, 2304–2310 (2011).
39. Quehenberger, F., Vasen, H. F. A. & van Houtwelingen, H. C. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J. Med. Genet.* **42**, 491–496 (2005).
40. Baglietto, L. et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J. Natl. Cancer Inst.* **102**, 193–201 (2010).
41. Balaguer, F. et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **5**, 379–387 (2007).

42. Barnetson, R. A. et al. Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. *Clin. Genet.* **72**, 551–555 (2007).
43. Boparai, K. S. et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterology* **135**, 2014–2018 (2008).
44. Croitoru, M. E. et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. *J. Natl. Cancer Inst.* **96**, 1631–1634 (2004).
45. Jenkins, M. A. et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. *Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol.* **15**, 312–314 (2006).
46. Lubbe, S. J., Di Bernardo, M. C., Chandler, I. P. & Houlston, R. S. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **27**, 3975–3980 (2009).
47. Out, A. A. et al. MUTYH gene variants and breast cancer in a Dutch case-control study. *Breast Cancer Res. Treat.* **134**, 219–227 (2012).
48. Santonocito, C. et al. Common genetic variants of MUTYH are not associated with cutaneous malignant melanoma: application of molecular screening by means of high-resolution melting technique in a pilot case-control study. *Int. J. Biol. Markers* **26**, 37–42 (2011).
49. Vogt, S. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology* **137**, 1976-1985.e1–10 (2009).
50. Win, A. K. et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. *Int. J. Cancer* **129**, 2256–2262 (2011).
51. Cleary, S. P. et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. *Gastroenterology* **136**, 1251–1260 (2009).
52. Weren, R. D. A. et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. *Nat. Genet.* **47**, 668–671 (2015).
53. Rivera, B., Castellsagué, E., Bah, I., van Kempen, L. C. & Foulkes, W. D. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. *N. Engl. J. Med.* **373**, 1985–1986 (2015).
54. Belhadj, S. et al. Delineating the Phenotypic Spectrum of the NTHL1-Associated Polyposis. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* **15**, 461–462 (2017).
55. Broderick, P. et al. Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients—a Systematic Review. *Gastroenterology* **152**, 75-77.e4 (2017).
56. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology* **135**, 419–428 (2008).
57. ten Broeke, S. W. et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **33**, 319–325 (2015).
58. Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat. Genet.* **45**, 136–144 (2013).
59. Bellido, F. et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **18**, 325–332 (2016).
60. Spier, I. et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int. J. Cancer* **137**, 320–331 (2015).
61. Pachlopnik Schmid, J. et al. Polymerase ε1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature ('FILS syndrome'). *J. Exp. Med.* **209**, 2323–2330 (2012).
62. Wimmer, K. et al. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. *Fam. Cancer* **16**, 67–71 (2017).
63. Bubien, V. et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J. Med. Genet.* **50**, 255–263 (2013).
64. Hobert, J. A. & Eng, C. PTEN hamartoma tumor syndrome: an overview. *Genet. Med. Off. J. Am. Coll. Med. Genet.* **11**, 687–694 (2009).
65. Nieuwenhuis, M. H. et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. *Fam. Cancer* **13**, 57–63 (2014).
66. Tan, M.-H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **18**, 400–407 (2012).
67. Jaeger, E. et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. *Nat. Genet.* **44**, 699–703 (2012).
68. Lieberman, S. et al. Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance. *Gastroenterology* **152**, 1876-1880.e1 (2017).
69. Jasperson, K. & Burt, R. W. The Genetics of Colorectal Cancer. *Surg. Oncol. Clin. N. Am.* **24**, 683–703 (2015).
70. Howe, J. R., Mitros, F. A. & Summers, R. W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. *Ann. Surg. Oncol.* **5**, 751–756 (1998).
71. Tomlinson, I. P. & Houlston, R. S. Peutz-Jeghers syndrome. *J. Med. Genet.* **34**, 1007–1011 (1997).
72. Hearle, N. et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **12**, 3209–3215 (2006).
73. Giardiello, F. M. et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* **119**, 1447–1453 (2000).
74. Chompret, A. et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. *Br. J. Cancer* **82**, 1932–1937 (2000).
75. Gonzalez, K. D. et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **27**, 1250–1256 (2009).
76. Olivier, M. et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res.* **63**, 6643–6650 (2003).
77. Ruijs, M. W. G. et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. *J. Med. Genet.* **47**, 421–428 (2010).
78. Hisada, M., Garber, J. E., Fung, C. Y., Fraumeni, J. F. & Li, F. P. Multiple primary cancers in families with Li-Fraumeni syndrome. *J. Natl. Cancer Inst.* **90**, 606–611 (1998).